Sinotherapeutics Inc. A (SHG:688247) — Stock Price
Sinotherapeutics Inc. A (SHG:688247) is currently trading at CN¥9.32 CNY, up 0.32% today. Over the past 52 weeks, shares have ranged between CN¥7.26 and CN¥12.69. This page tracks Sinotherapeutics Inc. A's live share price on the SHG exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Sinotherapeutics Inc. A market capitalisation.
Sinotherapeutics Inc. A (688247) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Sinotherapeutics Inc. A's daily closing share price and trading volume on the SHG exchange over the past year, giving a clear view of recent price momentum and liquidity.
Sinotherapeutics Inc. A Income Statement — Revenue, Profit & Earnings by Year
Sinotherapeutics Inc. A's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | CN¥446.57 Million | CN¥511.62 Million | CN¥299.87 Million | CN¥247.56 Million | CN¥315.47 Million |
| Cost of Revenue | CN¥270.54 Million | CN¥247.47 Million | CN¥132.26 Million | CN¥71.23 Million | CN¥69.00 Million |
| Gross Profit | CN¥176.03 Million | CN¥264.15 Million | CN¥167.61 Million | CN¥176.34 Million | CN¥246.47 Million |
| Research & Development | CN¥74.94 Million | CN¥84.92 Million | CN¥74.01 Million | CN¥76.02 Million | CN¥103.63 Million |
| SG&A | CN¥14.86 Million | CN¥17.14 Million | CN¥14.02 Million | CN¥10.40 Million | CN¥20.30 Million |
| Total Operating Expenses | CN¥385.05 Million | CN¥383.80 Million | CN¥247.21 Million | CN¥180.02 Million | CN¥195.22 Million |
| Operating Income | CN¥61.52 Million | CN¥127.81 Million | CN¥52.66 Million | CN¥67.54 Million | CN¥120.25 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | CN¥1.41K | CN¥2.55K | CN¥37.81K | CN¥213.52K | CN¥229.69K |
| Income Before Tax | CN¥53.34 Million | CN¥142.08 Million | CN¥65.99 Million | CN¥97.48 Million | CN¥149.01 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | CN¥47.48 Million | CN¥127.70 Million | CN¥61.07 Million | CN¥92.93 Million | CN¥134.92 Million |
Sinotherapeutics Inc. A Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Sinotherapeutics Inc. A's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | CN¥1.44 Billion | CN¥1.45 Billion | CN¥1.36 Billion | CN¥1.33 Billion | CN¥865.81 Million |
| Total Current Assets | CN¥934.87 Million | CN¥976.32 Million | CN¥952.01 Million | CN¥953.71 Million | CN¥618.83 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | CN¥339.34 Million | CN¥507.74 Million | — | — | — |
| Net Receivables | CN¥79.95 Million | CN¥103.52 Million | CN¥65.92 Million | CN¥64.30 Million | CN¥40.39 Million |
| Inventory | CN¥72.55 Million | CN¥102.42 Million | CN¥84.61 Million | CN¥29.38 Million | CN¥40.43 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | CN¥16.22 Million | CN¥18.39 Million | CN¥18.39 Million | CN¥18.39 Million | — |
| Total Liabilities | CN¥146.12 Million | CN¥180.30 Million | CN¥151.36 Million | CN¥155.05 Million | CN¥160.62 Million |
| Total Current Liabilities | CN¥82.96 Million | CN¥103.19 Million | CN¥90.72 Million | CN¥90.05 Million | CN¥89.52 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | CN¥1.29 Billion | CN¥1.27 Billion | CN¥1.21 Billion | CN¥1.18 Billion | CN¥705.19 Million |
| Retained Earnings | CN¥327.68 Million | CN¥310.02 Million | CN¥219.59 Million | CN¥188.38 Million | CN¥102.13 Million |
Sinotherapeutics Inc. A Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Sinotherapeutics Inc. A generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | CN¥95.33 Million | CN¥130.23 Million | CN¥12.96 Million | CN¥73.18 Million | CN¥145.77 Million |
| Capital Expenditures | CN¥41.56 Million | CN¥94.93 Million | CN¥38.96 Million | CN¥176.34 Million | CN¥16.01 Million |
| Free Cash Flow | CN¥53.77 Million | CN¥35.30 Million | CN¥-26.00 Million | CN¥-103.15 Million | CN¥129.77 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | CN¥27.84 Million | CN¥27.88 Million | CN¥28.11 Million | — | — |
| Stock-Based Compensation | — | — | — | — | CN¥7.94 Million |
| Depreciation | CN¥31.90 Million | CN¥24.83 Million | CN¥23.27 Million | CN¥26.43 Million | CN¥26.94 Million |
| Change in Cash | CN¥181.10 Million | CN¥-416.00 Million | CN¥-121.36 Million | CN¥251.50 Million | CN¥77.71 Million |
Sinotherapeutics Inc. A Earnings History — EPS Actual vs. Analyst Estimates
Track Sinotherapeutics Inc. A's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 31, 2023 | 0.02 | — | — |
| Dec 31, 2022 | 0.06 | — | — |
| Sep 30, 2022 | 0.06 | — | — |